Olanzapine

Generic Name
Olanzapine
Brand Names
Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
Drug Type
Small Molecule
Chemical Formula
C17H20N4S
CAS Number
132539-06-1
Unique Ingredient Identifier
N7U69T4SZR
Background

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.

Indication

Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.

Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.

As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.

Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.

Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.

Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.

Olanzapine is also indicated in combination with samidorphan for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.

Associated Conditions
Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Associated Therapies
-

Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-07-10
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
690
Registration Number
NCT00712686

Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-06-18
Last Posted Date
2009-01-21
Lead Sponsor
The New England Baptist Hospital
Target Recruit Count
495
Registration Number
NCT00699946
Locations
🇺🇸

New England Baptist Hospital, Boston, Massachusetts, United States

Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-06-06
Last Posted Date
2019-05-10
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
23
Registration Number
NCT00692185
Locations
🇺🇸

Eating Disorders Clinic, New York State Psychiatric Institute, New York, New York, United States

Phase IIA Study in Patients With Schizophrenia

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-05-30
Last Posted Date
2013-03-29
Lead Sponsor
AstraZeneca
Target Recruit Count
106
Registration Number
NCT00686998
Locations
🇺🇸

Research Site, Rockville, Maryland, United States

Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-05-28
Last Posted Date
2013-10-29
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
22
Registration Number
NCT00685334
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

🇨🇦

Toronto General Hospital, Toronto, Ontario, Canada

Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial

First Posted Date
2008-05-15
Last Posted Date
2009-01-30
Lead Sponsor
University of Virginia
Target Recruit Count
40
Registration Number
NCT00678457
Locations
🇺🇸

UVA CARE, Charlottesville, Virginia, United States

🇺🇸

UVA CARE Richmond, Richmond, Virginia, United States

Cardio Risk of Acute Schizophrenia Olanzapine Duke

First Posted Date
2008-05-06
Last Posted Date
2014-07-31
Lead Sponsor
Duke University
Registration Number
NCT00672464
Locations
🇺🇸

John Umstead Hospital, Butner, North Carolina, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-03-27
Last Posted Date
2014-05-08
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
462
Registration Number
NCT00645099

Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride

First Posted Date
2008-03-11
Last Posted Date
2018-01-19
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
180
Registration Number
NCT00632645
Locations
🇫🇷

CHU Henri Mondor, Creteil, France

Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-02-28
Last Posted Date
2008-02-28
Lead Sponsor
Leiden University Medical Center
Target Recruit Count
11
Registration Number
NCT00625170
Locations
🇳🇱

Leiden University Medical Center, Leiden, Netherlands

© Copyright 2024. All Rights Reserved by MedPath